Table 3. Univariate and multivariate cox regression analyses for overall survival in patients with nasopharyngeal carcinoma (unmatched complete datasets).

Variables	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Sex
Female vs. Male	0.39 (0.22-0.69)	0.001*	0.40 (0.23-0.72)	0.002*
Age
≥50 vs. <50	1.63 (1.05-2.51)	0.028*	1.85 (1.18-2.88)	0.007*
BMI
>25 vs. ≤25	0.75 (0.46-1.24)	0.264
T stage		0.009*		0.039*
T1	Ref.		Ref.
T2	1.77 (0.87-3.61)	0.114	1.67 (0.81-3.44)	0.167
T3	2.39 (1.21-4.72)	0.012*	2.11 (1.06-4.21)	0.034*
T4	3.199 (1.57-6.51)	0.001*	2.75 (1.34-5.66)	0.006*
N stage		0.027*		0.031*
N0	Ref.		Ref.
N1	2.34 (0.97-5.64)	0.060	2.24 (0.92-5.44)	0.075
N2	2.83 (1.20-6.65)	0.017	2.92 (1.23-6.94)	0.015*
N3	4.07 (1.59-10.41)	0.003	4.04 (1.54-10.61)	0.005*
chemotherapy
YES vs. NO	1.11 (0.70-1.76)	0.670
IMRT
YES vs. NO	0.79 (0.51-1.24)	0.310
SII
>403 vs. ≤403	2.34 (1.46-3.74)	<0.001*	2.26 (1.40-3.66)	0.001*a
NLR
>2.26 vs. ≤2.26	1.58 (1.04-2.38)	0.031*	1.66 (1.08-2.53)	0.020*b
PLR
>112 vs. ≤112	1.54 (1.01-2.35)	0.047*	1.54 (0.99-2.38)	0.051c
MLR
>0.25 vs. ≤0.25	1.98 (1.17-3.35)	0.011*	1.99 (1.17-3.39)	0.011*d

BMI: body mass index; IMRT: intensity-modulated radiotherapy; SII: systemic immune-inflammation index; PLR: platelet lymphocyte ratio; NLR: neutrophil lymphocyte ratio; MLR: monocyte lymphocyte ratio; HR: hazard ratio; CI: confidence interval; Ref: reference. ^a The variables (sex, age, T stage, N stage and SII) were tested in a multivariate analysis. ^b The variables (sex, age, T stage, N stage and NLR) were tested in a multivariate analysis. ^c The variables (sex, age, T stage, N stag and PLR) were tested in a multivariate analysis. ^d The variables (sex, age, T stage, N stag and MLR) were tested in a multivariate analysis.